A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis
A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.
Inclusion Criteria:
Exclusion Criteria:
North Massapequa, New York 11758, United States
Botucatu, 18618-687, Brazil
Wuhan, 430022, China
Xi'an, 710038, China
Hradec Kralova, 500 02, Czechia
Fujiidera-shi, 583-0027, Japan
Sumida Ku, 130 8575, Japan
Cluj-Napoca, 400061, Romania